Reports Q3 revenue $1.4B, consensus $1.35B. “The continued momentum in our Healthcare segment reflects solid procedure volume growth in the United States and the easing of supply chain constraints which allowed us to continue to reduce backlog levels. In addition, revenue within our Life Sciences segment improved during the quarter,” said Dan Carestio, President and CEO of STERIS. “Our revenue outlook for fiscal 2024 has increased as we continue to experience outperformance within the Healthcare segment, offsetting macro challenges impacting demand in our other segments.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STE:
- Tesla downgraded, UPS upgraded: Wall Street’s top analyst calls
- Steris resumed with an Overweight at KeyBanc
- STE Upcoming Earnings Report: What to Expect?
- STERIS Announces Dividend of $0.52 per share
- STERIS to Host a Conference Call for Fiscal 2024 Third Quarter Financial Results on February 8, 2024
